A new study of ovarian cancer cells from the University of Michigan Comprehensive Cancer Center, funded in part by an OCRF grant to Dr. Weiping Zou, reveals molecular changes within the tumor that prevent immunotherapy drugs from killing off the cancer. The research was published in Nature. Immunotherapy treatments have proven wildly successful in treating … Continued
For Immediate ReleaseSeptember 23, 2015 New Ovarian Cancer National Alliance research finds state lawmakers have power to dramatically improve access to ovarian cancer care and outcomes for the 21,000 women diagnosed each year WASHINGTON, D.C. — Today, the Ovarian Cancer National Alliance (OCNA) released groundbreaking new data in its report “50 States of Teal: Ovarian … Continued
Show the world that #tealislove. One mother is showing her love for her daughter Sarah who was diagnosed with ovarian cancer 5 years ago at the age of 28. Sarah is now in recurrence. Sarah’s mom created a page on Teal is Love because wants the world to know the signs and symptoms of ovarian … Continued
Q&A with Kris Wood, PhD Duke University 2015 Liz Tilberis Award OCRFA: Tell me about yourself. Kris Wood: I grew up in Georgetown, KY, a rural town in the central part of the state. My family lived in a house on my grandfather’s farm, which was a wonderful place to grow up– I spent … Continued
FOR IMMEDIATE RELEASESeptember 2, 2015 Sherry Pollex and the Ovarian Cancer National Alliance launch “The TealAppeal” to raise ovarian cancer awarenessPollex, Ovarian Cancer National Alliance, Martin Truex Jr., and Danica Patrickjoin forces during September’s National Ovarian Cancer Awareness Month, tosave more women’s lives DARLINGTON, SC — On Sunday, Sherry Pollex and the Ovarian Cancer National … Continued
FOR IMMEDIATE RELEASE June 15, 2015 Ovarian Cancer National Alliance honored for advocacy work OCNA called “leading advocacy organization for women impacted by ovarian cancer” WASHINGTON, DC — On Saturday, June 20, the Ovarian Cancer National Alliance (OCNA) will be honored by Facing Our Risk of Cancer Empowered (FORCE) at the 2015 Spirit of Empowerment … Continued
(9/11/15) By Alan D. D’Andrea, MD, Dana-Farber Cancer Institute and Harvard Medical School, and Elizabeth M. Swisher, MD, University of Washington September is Ovarian Cancer Awareness Month, when we scientists and advocates renew our determination to find new solutions to this devastating disease. This year we are pleased to have seen some encouraging signs. At … Continued
The largest private funder of ovarian cancer research awarded $6.3 million in grants while also launching new events and partnerships (September 11, 2015) –Ovarian Cancer Research Fund (OCRF), has awarded $6.3 million in grants to scientists working to cure ovarian cancer, as well as to hospitals supporting patients through OCRF’s signature Woman to Woman program. … Continued
Ovarian Cancer Research Fund’s Luxury Shopping Event to be held at Grand Canal Shoppes at The Venetian & The Palazzo and Fashion Show, September 19-20 Las Vegas, NV – Ovarian Cancer Research Fund (OCRF) will bring its popular Super Saturday shopping event to Grand Canal Shoppes at The Venetian & The Palazzo, and Fashion Show … Continued
(August 26, 2015) Women with epithelial ovarian cancer who happened to be taking nonselective beta-blockers for hypertension survived longer than those who were not taking the drugs, according to a large multicenter retrospective study. The study was funded in part by an OCRF grant to Dr. Anil Sood at MD Anderson Cancer Center. Survival was … Continued
(August 19, 2015) Whereas chemotherapy kills cancer cells only while it is being administered, immunotherapy can lead to an adaptive immune response that persists long after treatment is ceased. By simple analogy, whereas aspirin provides temporary pain relief, a polio vaccine provides lifelong protection. Unfortunately, just as tumors develop resistance to conventional therapies, tumors also … Continued
On August 3, 2015 the New York Times published an article about the use of IP chemotherapy in the treatment of ovarian cancer. Our CEO, Calaneet Balas joined with Ovarian Cancer Research Fund CEO, Audra Moran, to write a response to the New York Times. Click the plus sign to see their Letter to the Editor.
Get email updates about research news, action alerts, and ways to join the fight.
